Jay Parrish
Chairman and CEO of Pretzel Therapeutics
United States
Overview
Work Experience
Chairman and CEO
2021 - Current
Developing treatments to address the genetic roots of mitochondrial dysfunction
Pretzel Therapeutics mission is to develop groundbreaking therapies to reverse mitochondrial dysfunction through mitochondrial biology.
Raised $72,500,000.00 from University of Cambridge Enterprise, Karolinska, Google Ventures, Mubadala Capital Ventures, Angelini Ventures, Invus, EIR Ventures, HealthCap, ARCH Venture Partners and GU Ventures.
Venture Partner
2016
We’re catalyzing discoveries that prevent, detect, and cure disease
ARCH is a venture firm that focuses on life science discoveries to prevent, detect, and cure disease.
Chairman of the Board
2020
Series A company focused on small molecule solutions to several types of kidney stones (oxalate and cystine) and high-recurrent patient populations within. Formerly known as GyanRx.
Co-Founder and Board Member
2022
Strategic Advisor
2023
Magnet Biomedicine’s modular TrueGlue™ technology enables the systematic discovery of molecular glues towards the treatment of human disease. https://magnetbio.com
Magnet Biomedicine is a biotechnology research platform specializing in discovering true molecular glues.
Raised $50,000,000.00 from Newpath Management and ARCH Venture Partners.
Co-Founder and Member Board Of Directors
2019
Harnessing the power of the repeatome to develop a new class of therapies for cancer and autoimmune diseases
ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.
Raised $199,000,000.00 from Mass General Brigham Ventures, Casdin Capital, Section 32, Curie.Bio, Sanofi Ventures, Google Ventures, Mirae Asset Capital, Luma Group, Axon Ventures and Andreessen Horowitz.
Strategic Advisor
2022
Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines to treat human disease in ways that were not previously possible
Orbital Therapeutics is a biotechnology company that develops RNA-based medicines to treat disease in humans.
Raised $270,000,000.00 from Andreessen Horowitz, Invus, Redmile Group, EXOR N.V., Rellim Capital Management, ARCH Venture Partners, Newpath Management, Abu Dhabi Growth Fund, Agent Capital and iGlobe Partners.
Board Observer
2021
Gate Bioscience is developing Molecular Gates, a new frontier in protein elimination
Gate Bioscience specializes in a small molecule modality to treat biology’s intractable diseases.
Raised $60,000,000.00 from Google Ventures, Versant Ventures, ARCH Venture Partners and Andreessen Horowitz.
Member Board Of Directors
2021
Interline Therapeutics is a drug discovery company focused on systematically elucidating protein communities to define molecular mechanisms of disease.
Interline Therapeutics is a drug discovery platform that enables the company to map and correct dysfunctional protein communities.
Raised $92,000,000.00 from Foresite Capital and ARCH Venture Partners.
Strategic Advisor
2021 - 2024
Sold to Biogen for $1.8B ($1.15B upfront and $650M in milestones)
Human Immunology Biosciences is a biotechnology company that focuses on developing therapies for immune-mediated diseases.
Raised $215,000,000.00 from Alpha Wave Global, Jeito Capital, ARCH Venture Partners, Arkin Holdings and Viking Global Investors.